Seattle Genetics Adds Richard Flavell, Ph.D., to Scientific Advisory Board.BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq:SGEN SGEN Signal/System Generator ) announced today that Richard A. Flavell, Ph.D., a renowned scientist with over 30 years of biotechnology and academic experience, has been added to the company's scientific advisory board. In this role, he will provide scientific input on research and development of Seattle Genetics' multiple product candidates and technologies. Dr. Flavell currently serves as Chairman and Professor of Immunobiology at Yale University Yale University, at New Haven, Conn.; coeducational. Chartered as a collegiate school for men in 1701 largely as a result of the efforts of James Pierpont, it opened at Killingworth (now Clinton) in 1702, moved (1707) to Saybrook (now Old Saybrook), and in 1716 was School of Medicine. He is also a Howard Hughes Medical Institute Howard Hughes Medical Institute, (HHMI), nonprofit medical research organization founded in 1953 by Howard Hughes and largly funded from proceeds of the 1984–85 sale of Hughes Aircraft. Headquartered in Chevy Chase, Md. Investigator. "Dr. Flavell has extensive experience in therapeutic product development both through his impressive academic career and his former role as Chief Scientific Officer of Biogen," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "His knowledge and background will be a valuable resource to Seattle Genetics as we continue advancing our programs for the treatment of patients with cancer and immunologic diseases." Prior to his current position at Yale University, Dr. Flavell was President and Chief Scientific Officer of Biogen, Inc. He has served as a scientific advisor for numerous biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. since 1980, including Celltech, CuraGen and Biogen, and is a member of the Cancer Research United Kingdom Scientific Committee. He is an author of over 500 scientific publications, editor of numerous scientific journals, a fellow of the Royal Society Fellow of the Royal Society is an honour accorded to distinguished scientists and a category of membership of the Royal Society. Fellows are entitled to put the letters FRS after their name. Up to 44 new fellows are elected each year by ballot of the existing fellows. , and a member of the National Academy of Sciences and several other distinguished societies. Dr. Flavell received his Ph.D. in biochemistry from the University of Hull in Great Britain Great Britain, officially United Kingdom of Great Britain and Northern Ireland, constitutional monarchy (2005 est. pop. 60,441,000), 94,226 sq mi (244,044 sq km), on the British Isles, off W Europe. The country is often referred to simply as Britain. , with subsequent post-doctoral study at the University of Amsterdam and the University of Zurich History The University of Zurich was founded in 1833 with existing colleges of theology (founded by Huldrych Zwingli in 1525), law and medicine merged together with a new faculty of Philosophy. . About Seattle Genetics Seattle Genetics is a biotechnology company focused on the development of monoclonal antibody-based therapies for the treatment of cancer and immunologic diseases. The company is conducting clinical and preclinical development of a diverse portfolio of product candidates in a variety of oncology and immunology settings. In addition, Seattle Genetics has developed proprietary antibody-drug conjugate conjugate /con·ju·gate/ (kon´jdbobr-gat) 1. paired, or equally coupled; working in unison. 2. a conjugate diameter of the pelvic inlet; used alone usually to denote the true conjugate diameter; see (ADC (1) See A/D converter. (2) (Apple Display Connector) A peripheral connector from Apple that combines digital video display, USB and power in one cable. ) technology comprised of highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). . The company currently has license agreements for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen and MedImmune. More information about Seattle Genetics' pipeline and technologies can be found at www.seattlegenetics.com. Certain of the statements made in this press release are forward-looking. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Specifically, statements regarding continued advancement of the company's programs and technologies are forward-looking, and actual results may differ materially from these statements for various reasons. Factors that may cause such a difference include risks related to adverse clinical results as our product candidates move into and advance in clinical trials, risks inherent in early-stage development and failure by Seattle Genetics to secure collaborators or failure of those collaborators to perform their contractual obligations. More information about the risks and uncertainties faced by Seattle Genetics is contained in the Company's filings with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion